DiscoverQuestioning MedicineEpisode 389: 400. CRP, Lipoprotein A, LDL for cardiac risk assessment
Episode 389: 400. CRP, Lipoprotein A, LDL for cardiac risk assessment

Episode 389: 400. CRP, Lipoprotein A, LDL for cardiac risk assessment

Update: 2025-05-29
Share

Description

https://www.nejm.org/doi/full/10.1056/NEJMoa2405182?query=recirc_Semantic

 

 

Key Takeaways



  1. Extended Predictive Value of Biomarkers:

    • High-sensitivity C-reactive protein (CRP), LDL cholesterol, and lipoprotein(a) levels were found to be predictive of cardiovascular events over a 30-year period.

    • These markers contribute independently to long-term cardiovascular risk beyond traditional 10-year risk estimates.




  2. Study Design and Population:

    • The study enrolled 27,939 initially healthy U.S. women who were followed for 30 years.

    • The primary endpoint was the occurrence of a first major adverse cardiovascular event, including myocardial infarction, coronary revascularization, stroke, or death from cardiovascular causes.




  3. Predictive Strength of Biomarkers:

    • Among the biomarkers, high-sensitivity CRP showed the strongest association with future cardiovascular events (hazard ratio for top quintile: 1.70).

    • LDL cholesterol and lipoprotein(a) also significantly predicted risk, albeit to a slightly lower degree (hazard ratios: 1.36 and 1.33, respectively).  NOT STATIN WITH CRP




  4. Implications for Clinical Practice:

    • Combining all three biomarkers may offer the best method for identifying high-risk individuals who might benefit from early intervention.   YOU HAVE TO PROSPECTIVELY VALIDATE THIS

    • The study supports extending cardiovascular prevention strategies beyond traditional risk assessments.

    • Lifestyle and pharmacologic interventions should target multiple pathways, including lipid levels and inflammation.




Key Limitations



  1. Study Population:

    • The study cohort predominantly consisted of female health professionals who are mostly White (94%), which may limit generalizability.

    • The results may not extend to males or more diverse populations without further studies.




  2. Absence of Repeated Measures:

    • Biomarkers were measured only at baseline without repeated measures over time.

    • This limits the ability to observe changes in biomarker levels and their association with risk over time.




  3. Statin Use Data:

    • Increasing use of statins over the study period was not thoroughly considered in initial analyses, and detailed data on adherence and duration are lacking.

    • Sensitivity analyses attempted to account for this by censoring data at the time of first statin prescription, but residual confounding may be present.



Concerns with Study Design



  1. Cohort Composition:

    • The study's focus on health professionals might have led to better access to healthcare and healthier lifestyle choices, potentially skewing outcomes.

    • Non-White participants were underrepresented, raising concerns about the applicability of findings to more diverse groups.




  2. Single Time Point Measurement:
    • Only baseline biomarker levels were used for long-term prediction, which may not account for variability and changes in risk factors over time.



Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Episode 389: 400. CRP, Lipoprotein A, LDL for cardiac risk assessment

Episode 389: 400. CRP, Lipoprotein A, LDL for cardiac risk assessment

Questioning Medicine